Review





Similar Products

cb839  (MedChemExpress)
96
MedChemExpress cb839
Cb839, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb839/product/MedChemExpress
Average 96 stars, based on 1 article reviews
cb839 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cb839  (Selleck Chemicals)
95
Selleck Chemicals cb839
Cb839, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb839/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
cb839 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
cb839 telaglenastat  (Selleck Chemicals)
95
Selleck Chemicals cb839 telaglenastat
( A ) Viability curves showing titration of GS inhibitor, MSO, alone (left panel) or in combination with sub-lethal doses of GLS inhibitor, <t>CB839</t> (right panel) in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left * p = 0.04, ** p = 0.005; right **** p ≤ 0.0001, ** p = 0.005). ( B ) Viability curves showing titration of the GLS inhibitor, CB839, alone (left panel) or in combination with sub-lethal doses of the GS inhibitor, MSO (right panel), in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left **** p ≤ 0.0001, ** p = 0.0096) (right **** p ≤ 0.0001, * p = 0.014, ** p = 0.003, * p = 0.025). ( C ) Schematic representation of the glutamate-glutamine cycle and the drugs that inhibit the corresponding enzymes in this pathway. ( D ) Survival graphs of SW48 cells treated with single doses of GLS inhibitor (CB839) 100 nM, GS inhibitor (MSO) 2 mM alone or in combination in full media (left panel) and low nutrient media (right panel) conditions. Data represents the mean of 4 biological replicates. Box plots show the median (centre line), interquartile range (box), and whiskers extending to the minimum and maximum values. Statistical analyses were performed using two-way ANOVA followed by Dunnett’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (RPMI WT **** p ≤ 0.0001; G12A ** p = 0.01, **** p ≤ 0.0001; Low nutrients WT * p = 0.014, **** p ≤ 0.0001; G12A *** p = 0.0003, **** p ≤ 0.0001; G12C *** p = 0.0004, **** p ≤ 0.0001; G12D **** p ≤ 0.0001; G12V ** p = 0.0015, **** p ≤ 0.0001). .
Cb839 Telaglenastat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb839 telaglenastat/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
cb839 telaglenastat - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

Image Search Results


( A ) Viability curves showing titration of GS inhibitor, MSO, alone (left panel) or in combination with sub-lethal doses of GLS inhibitor, CB839 (right panel) in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left * p = 0.04, ** p = 0.005; right **** p ≤ 0.0001, ** p = 0.005). ( B ) Viability curves showing titration of the GLS inhibitor, CB839, alone (left panel) or in combination with sub-lethal doses of the GS inhibitor, MSO (right panel), in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left **** p ≤ 0.0001, ** p = 0.0096) (right **** p ≤ 0.0001, * p = 0.014, ** p = 0.003, * p = 0.025). ( C ) Schematic representation of the glutamate-glutamine cycle and the drugs that inhibit the corresponding enzymes in this pathway. ( D ) Survival graphs of SW48 cells treated with single doses of GLS inhibitor (CB839) 100 nM, GS inhibitor (MSO) 2 mM alone or in combination in full media (left panel) and low nutrient media (right panel) conditions. Data represents the mean of 4 biological replicates. Box plots show the median (centre line), interquartile range (box), and whiskers extending to the minimum and maximum values. Statistical analyses were performed using two-way ANOVA followed by Dunnett’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (RPMI WT **** p ≤ 0.0001; G12A ** p = 0.01, **** p ≤ 0.0001; Low nutrients WT * p = 0.014, **** p ≤ 0.0001; G12A *** p = 0.0003, **** p ≤ 0.0001; G12C *** p = 0.0004, **** p ≤ 0.0001; G12D **** p ≤ 0.0001; G12V ** p = 0.0015, **** p ≤ 0.0001). .

Journal: EMBO Reports

Article Title: FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer

doi: 10.1038/s44319-025-00641-z

Figure Lengend Snippet: ( A ) Viability curves showing titration of GS inhibitor, MSO, alone (left panel) or in combination with sub-lethal doses of GLS inhibitor, CB839 (right panel) in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left * p = 0.04, ** p = 0.005; right **** p ≤ 0.0001, ** p = 0.005). ( B ) Viability curves showing titration of the GLS inhibitor, CB839, alone (left panel) or in combination with sub-lethal doses of the GS inhibitor, MSO (right panel), in SW48 cells (low nutrient conditions). Data is presented as mean and standard error. Statistical analyses of Area Under the Curve (AUC) from 3 biological repeats were performed using one-way ANOVA followed by Sidak’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (left **** p ≤ 0.0001, ** p = 0.0096) (right **** p ≤ 0.0001, * p = 0.014, ** p = 0.003, * p = 0.025). ( C ) Schematic representation of the glutamate-glutamine cycle and the drugs that inhibit the corresponding enzymes in this pathway. ( D ) Survival graphs of SW48 cells treated with single doses of GLS inhibitor (CB839) 100 nM, GS inhibitor (MSO) 2 mM alone or in combination in full media (left panel) and low nutrient media (right panel) conditions. Data represents the mean of 4 biological replicates. Box plots show the median (centre line), interquartile range (box), and whiskers extending to the minimum and maximum values. Statistical analyses were performed using two-way ANOVA followed by Dunnett’s multiple comparisons test for all comparisons. Only statistically significant p values are shown (RPMI WT **** p ≤ 0.0001; G12A ** p = 0.01, **** p ≤ 0.0001; Low nutrients WT * p = 0.014, **** p ≤ 0.0001; G12A *** p = 0.0003, **** p ≤ 0.0001; G12C *** p = 0.0004, **** p ≤ 0.0001; G12D **** p ≤ 0.0001; G12V ** p = 0.0015, **** p ≤ 0.0001). .

Article Snippet: CB839 (Telaglenastat) , Selleckchem , Cat#S7655.

Techniques: Titration